Bristol Myers Squibb Co (BMY) SEC Filing 8-K Material Event for the period ending Wednesday, February 14, 2018

Bristol Myers Squibb Co

CIK: 14272 Ticker: BMY

View differences made from one to another to evaluate Bristol Myers Squibb Co's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Bristol Myers Squibb Co.


Assess how Bristol Myers Squibb Co's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Bristol Myers Squibb Co's Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Bristol Myers Squibb Co provided additional information to their SEC Filing as exhibits

Ticker: BMY
CIK: 14272
Form Type: 8-K Corporate News
Accession Number: 0001140361-18-008250
Submitted to the SEC: Wed Feb 14 2018 4:54:19 PM EST
Accepted by the SEC: Wed Feb 14 2018
Period: Wednesday, February 14, 2018
Industry: Pharmaceutical Preparations
  1. Financial Exhibit
  2. Other Events

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: